AIDS Research and Therapy

metrics 2024

Fostering collaboration to combat HIV/AIDS.

Introduction

AIDS Research and Therapy is a prestigious peer-reviewed journal dedicated to disseminating cutting-edge research in the fields of AIDS and HIV therapy. Published by BMC, this Open Access journal has been freely available since its inception in 2004, facilitating global access to vital research findings. Based in the United Kingdom, the journal covers a diverse range of topics including molecular medicine, pharmacology, and virology, making it a crucial resource for researchers and clinicians alike. Recognized for its strong impact within the scientific community, it holds a Q2 quartile ranking in multiple categories as of 2023, including Molecular Medicine and Pharmacology. With an aim to enhance understanding and improve clinical outcomes for those affected by HIV/AIDS, AIDS Research and Therapy serves as an essential platform for the exchange of innovative ideas and practices that can inform future therapies and interventions. Researchers, professionals, and students seeking high-quality, peer-reviewed content will find this journal invaluable in advancing their knowledge and efforts in combating the HIV/AIDS epidemic.

Metrics 2024

SCIMAGO Journal Rank0.87
Journal Impact Factor2.10
Journal Impact Factor (5 years)2.40
H-Index49
Journal IF Without Self2.10
Eigen Factor0.00
Normal Eigen Factor0.48
Influence0.87
Immediacy Index0.50
Cited Half Life4.90
Citing Half Life6.00
JCI0.41
Total Documents861
WOS Total Citations1381
SCIMAGO Total Citations5012
SCIMAGO SELF Citations133
Scopus Journal Rank0.87
Cites / Document (2 Years)2.18
Cites / Document (3 Years)2.37
Cites / Document (4 Years)2.50

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #130/272
Percentile 52.21
Quartile Q2
Virology in Immunology and Microbiology
Rank #49/80
Percentile 38.75
Quartile Q3
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #120/178
Percentile 32.58
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 84/132
Percentile 36.70
Quartile Q3

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 90/132
Percentile 31.82
Quartile Q3

Quartile History

Similar Journals

AIDS AND BEHAVIOR

Advancing understanding of HIV/AIDS behaviors.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1090-7165Frequency: 12 issues/year

AIDS AND BEHAVIOR, published by SPRINGER/PLENUM PUBLISHERS, is a leading scholarly journal dedicated to the interdisciplinary study of HIV/AIDS, focusing particularly on the behavioral aspects of the epidemic. With an impressive impact factor reflected in its Q1 rankings across key categories including Infectious Diseases, Public Health, and Social Psychology, this journal serves as a vital resource for researchers, clinicians, and public health professionals. It encompasses a wide scope of research, from the psychosocial factors influencing HIV transmission to innovative interventions that promote safe practices. Although it does not offer open access, the journal's rigorous peer-review process ensures the dissemination of high-quality, impactful research. Covering data from 1997 to 2024, AIDS AND BEHAVIOR is positioned at the forefront of advancements in the field, making it an essential addition to any academic library and a must-read for those involved in combating HIV/AIDS.

Revista Chilena de Infectologia

Illuminating the path in infectious disease research.
Publisher: SOC CHILENA INFECTOLOGIAISSN: 0716-1018Frequency: 6 issues/year

Revista Chilena de Infectologia is an esteemed academic journal dedicated to the field of infectious diseases and public health. Published by the SOC CHILENA INFECTOLOGIA, this journal has been pivotal in disseminating crucial research findings since its inception in 2000. While operating under ISSN 0716-1018 and E-ISSN 0717-6341, it aims to contribute to the understanding of both local and global health issues, particularly within the context of Chile. Currently, it holds a Q4 ranking in both the Infectious Diseases and Public Health, Environmental and Occupational Health categories as of 2023, reflecting its unique position among emerging voices in the field. The journal aspires to foster collaboration among researchers, professionals, and students by offering a platform for innovative studies and discussions that address pressing health challenges. Although it is not an Open Access journal, access options through institutional subscriptions are encouraged for a comprehensive review of its significant contributions to infectious disease research.

Acta Facultatis Medicae Naissensis

Fostering Dialogue in Diverse Medical Disciplines
Publisher: UNIV NIS, FAC MEDICINEISSN: 0351-6083Frequency: 4 issues/year

Acta Facultatis Medicae Naissensis is an esteemed open-access journal published by the University of Niš, Faculty of Medicine, situated in Serbia. Since its inception in 2009, this journal has been a vital platform for the dissemination of innovative research findings in the field of Medicine, particularly focusing on miscellaneous areas within the discipline. With an ISSN of 0351-6083 and an E-ISSN of 2217-2521, it operates under a commitment to free accessibility, enhancing visibility for authors and readers alike since 2012. In the 2023 categorization, it holds a respectable Q4 ranking in Medicine (Miscellaneous) and positions itself at the 34th percentile among general medicine publications in Scopus, reflecting its growing academic impact. Researchers, professionals, and students seeking an interactive scholarly exchange in medicine will find Acta Facultatis Medicae Naissensis a rich resource, contributing significantly to the understanding of health sciences and clinical practice through its diverse range of articles.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Elevating research standards in infectious diseases.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1525-4135Frequency: 15 issues/year

JAIDS - Journal of Acquired Immune Deficiency Syndromes, is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamics of HIV/AIDS and its broader implications in the fields of infectious diseases and pharmacology. With an esteemed impact factor that places it in the prestigious Q1 category for both Infectious Diseases and Pharmacology (medical) as of 2023, this journal aims to provide a platform for groundbreaking research, clinical findings, and innovative therapies relevant to the management and prevention of HIV/AIDS. The journal's rigorous editorial standards and commitment to advancing knowledge make it an essential resource for researchers, healthcare professionals, and students invested in the global response to AIDS. Although the journal does not currently offer open access options, it remains instrumental in disseminating high-quality research that shapes clinical practices and policy developments in the field.

HIV Research & Clinical Practice

Empowering clinicians with cutting-edge HIV strategies.
Publisher: TAYLOR & FRANCIS LTDISSN: 2578-7489Frequency: 6 issues/year

HIV Research & Clinical Practice, published by Taylor & Francis Ltd, is an essential open-access journal dedicated to advancing the knowledge and understanding of HIV-related research and clinical practices. With an ISSN of 2578-7489 and E-ISSN 2578-7470, this acclaimed journal is committed to disseminating cutting-edge studies and innovative treatment strategies within the infectious diseases and pharmacology fields, achieving a commendable Q2 ranking in both categories as of 2023. The journal's scope encompasses a broad range of topics from basic science to clinical application, providing a vital platform for researchers, clinicians, and students to exchange insights and foster collaboration. As an open-access publication since 2022, it ensures that high-quality research is accessible to a global audience, encouraging a greater understanding of HIV and its implications for public health. With its base in the United Kingdom and a convergence period from 2019 to 2024, HIV Research & Clinical Practice stands at the forefront of the fight against HIV/AIDS, making significant contributions to the clinical community and beyond.

AIDS RESEARCH AND HUMAN RETROVIRUSES

Connecting Researchers for a Healthier Tomorrow
Publisher: MARY ANN LIEBERT, INCISSN: 0889-2229Frequency: 12 issues/year

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

AIDS REVIEWS

Delivering comprehensive insights into AIDS advancements.
Publisher: PERMANYER PUBLISSN: 1139-6121Frequency: 4 issues/year

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.

CLINICAL AND EXPERIMENTAL MEDICINE

Unlocking the Future of Medicine Through Collaboration
Publisher: SPRINGER-VERLAG ITALIA SRLISSN: 1591-8890Frequency: 4 issues/year

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

Universa Medicina

Fostering collaboration to transform medical science.
Publisher: TRISAKTI UNIV, FAC MEDICINEISSN: 1907-3062Frequency: 3 issues/year

Universa Medicina is a distinguished open-access journal published by the Faculty of Medicine, Trisakti University, focusing on a broad spectrum of medical disciplines. It has established itself as a vital resource for researchers, healthcare professionals, and students seeking to advance their knowledge and contribute to medical science since its inception in 2009. With an ISSN of 1907-3062 and an E-ISSN of 2407-2230, the journal emphasizes the dissemination of high-quality research, reviews, and innovative case studies that address critical health issues in both local and global contexts. Although its H-index and Scopus ranking data are not currently available, Universa Medicina's commitment to open access ensures the widest possible reach and impact of its published articles. This journal serves as an essential platform for fostering collaboration and dialogue within the medical community, facilitating the exchange of ideas and advancing the frontiers of health knowledge in Indonesia and beyond.

Lancet HIV

Championing evidence-based approaches to HIV management.
Publisher: ELSEVIER INCISSN: 2352-3018Frequency: 12 issues/year

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.